Gsk Plc (GSK.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2000 | 09-2000 | 06-2000 | 03-2000 | |
| Cash Flows From Operating Activities | ||||
| Other Working Capital | N/A | N/A | -55,000 | -145,000 |
| Other Operating Activity | 0 | 0 | 55,000 | 145,000 |
| Operating Cash Flow | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Investing Activities | ||||
| PPE Investments | N/A | N/A | 40,000 | -197,000 |
| Net Acquisitions | N/A | N/A | -317,000 | -22,000 |
| Purchase Of Investment | N/A | N/A | N/A | -852,000 |
| Sale Of Investment | N/A | N/A | N/A | 16,000 |
| Other Investing Activity | -484,000 | 157,000 | 1,153,000 | 22,000 |
| Investing Cash Flow | $-484,000 | $157,000 | $876,000 | $-1,033,000 |
| Cash Flows From Financing Activities | ||||
| Common Stock Issued | N/A | N/A | 10,000 | 34,000 |
| Dividend Paid | N/A | N/A | -649,000 | -147,000 |
| Other Financing Activity | -546,000 | -11,000 | 615,000 | 148,000 |
| Financing Cash Flow | $-546,000 | $-11,000 | $-24,000 | $35,000 |
| End Cash Position | 1,311,000 | 3,745,000 | -185,000 | -439,000 |
| Net Cash Flow | $-2,923,000 | $3,930,000 | $254,000 | $-439,000 |
| Free Cash Flow | ||||
| Capital Expenditure | N/A | N/A | N/A | -246,000 |
| Free Cash Flow | 0 | 0 | 0 | -246,000 |